Electric field therapy before surgery for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a wearable device that uses electric fields (called tumor treating fields) before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve outcomes for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage I, II, or III non-small cell lung cancer and are scheduled for surgery to remove the tumor.
- You have not had any prior treatment for this lung cancer and you are not planning to receive chemotherapy or radiation before surgery.
- You are at least 22 years old and you are generally able to care for yourself (can be up and about, though not necessarily fully active).
- You agree to use effective birth control during the study and for 30 days after treatment ends, if you or your partner could become pregnant.
- You do not have an active serious infection, heart problems, or other uncontrolled conditions, and you don't have electronic implants like a pacemaker.
- You are willing to provide a fresh tissue sample from a biopsy if needed, and you can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a wearable device that sends electric fields (called Tumour Treating Fields) to the chest area, which may help slow or stop cancer growth. It is for people with non-small cell lung cancer that has a specific genetic change called EGFR mutation.
This trial tests a new treatment that uses short electrical pulses (pulsed electric field ablation) to destroy small lung tumors. It may be an option for people with limited, early-stage non-small cell lung cancer who can tolerate a minimally invasive procedure.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.